United Therapeutics (NSDQ:UTHR) announced today that it received FDA clearance for its Tyvaso inhalation solution for pulmonary hypertension.
Research Triangle Park, N.C.-based United Therapeutics’ Tyvaso (treprostinil) inhalation solution is designed to treat patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) to improve exercise ability, according to a news release.
Get the full story at our sister site, Drug Delivery Business News.